Ironwood Pharmaceuticals, Inc. - (IRWD): Price and Financial Metrics
GET POWR RATINGS... FREE!
IRWD POWR Grades
- Quality is the dimension where IRWD ranks best; there it ranks ahead of 99.71% of US stocks.
- The strongest trend for IRWD is in Momentum, which has been heading down over the past 31 weeks.
- IRWD ranks lowest in Momentum; there it ranks in the 5th percentile.
IRWD Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for IRWD is 3.62 -- better than 87.68% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 14.76 for Ironwood Pharmaceuticals Inc; that's greater than it is for 96.25% of US stocks.
- The volatility of Ironwood Pharmaceuticals Inc's share price is greater than that of just 12.37% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Ironwood Pharmaceuticals Inc, a group of peers worth examining would be ZIXI, BHTG, TSC, MCF, and PHUN.
- IRWD's SEC filings can be seen here. And to visit Ironwood Pharmaceuticals Inc's official web site, go to www.ironwoodpharma.com.
IRWD Price Target
For more insight on analysts targets of IRWD, see our IRWD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.67 | Average Broker Recommendation | 1.71 (Moderate Buy) |
IRWD Stock Price Chart Interactive Chart >
IRWD Price/Volume Stats
| Current price | $11.72 | 52-week high | $12.63 |
| Prev. close | $11.47 | 52-week low | $8.63 |
| Day low | $11.37 | Volume | 3,585,800 |
| Day high | $11.76 | Avg. volume | 1,985,063 |
| 50-day MA | $11.32 | Dividend yield | N/A |
| 200-day MA | $10.79 | Market Cap | 1.90B |
Ironwood Pharmaceuticals, Inc. - (IRWD) Company Bio
Ironwood Pharmaceuticals engages in the research, development, and commercialization of human therapeutic products, with a key focus being the treatment of adult men and women suffering from irritable bowel syndrome. The company was founded in 1998 and is based in Cambridge, Massachusetts.
Latest IRWD News From Around the Web
Below are the latest news stories about Ironwood Pharmaceuticals Inc that investors may wish to consider to help them evaluate IRWD as an investment opportunity.
Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)BOSTON, Jun 16, 2021--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The American College of Gastroenterology – published full results from the company’s Phase IIIb clinical trial evaluating LINZESS® (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation (IBS-C). The results, which can be viewed here, demonstrated |
Top Pharmaceutical Stocks for Q3 2021These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2021. |
A Look At Ironwood Pharmaceuticals' (NASDAQ:IRWD) Share Price ReturnsAs an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock... |
Ironwood Pharmaceuticals names Thomas McCourt permanent CEOIronwood Pharmaceuticals (IRWD) announces the appointment of Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as the company's permanent chief executive officer.McCourt has also been appointed to serve on Ironwood’s board, bringing the total number of directors to 11.Ironwood also announces that Gina Consylman plans to step down... |
Ironwood Pharmaceuticals Announces Leadership UpdatesIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood’s Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors. |
IRWD Price Returns
| 1-mo | -5.71% |
| 3-mo | 4.18% |
| 6-mo | -3.54% |
| 1-year | 21.96% |
| 3-year | -36.99% |
| 5-year | -7.86% |
| YTD | 2.90% |
| 2020 | -14.43% |
| 2019 | 28.47% |
| 2018 | -30.89% |
| 2017 | -1.96% |
| 2016 | 31.92% |
Continue Researching IRWD
Here are a few links from around the web to help you further your research on Ironwood Pharmaceuticals Inc's stock as an investment opportunity:Ironwood Pharmaceuticals Inc (IRWD) Stock Price | Nasdaq
Ironwood Pharmaceuticals Inc (IRWD) Stock Quote, History and News - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...